Nutritional Secondary Hyperparathyroidism

Nutritional secondary hyperparathyroidism (NSHP) is a metabolic bone disease characterized by excessive secretion of parathyroid hormone (PTH) secondary to a dietary imbalance of calcium, phosphorus, and vitamin D. It is most commonly observed in growing animals fed an all-meat diet or diets with an inverted calcium-to-phosphorus ratio (Ca:P < 1:1), leading to hypocalcemia and compensatory hyperparathyroidism. The condition results in increased osteoclastic bone resorption, fibrous osteodystrophy, and pathological fractures. NSHP is a classic example of a nutritional disorder causing endocrine dysfunction, and it is reversible if diagnosed early and treated appropriately.

The primary etiology of NSHP is a dietary deficiency of calcium, an excess of phosphorus, or a deficiency of vitamin D, often in combination. The most common cause is feeding an all-meat diet (e.g., beef heart, liver, or chicken) without bone or calcium supplementation, which is naturally high in phosphorus and low in calcium. Other causes include feeding unbalanced homemade diets, diets with excessive cereal grains (high phytate content that binds calcium), or commercial diets with an improper Ca:P ratio. Vitamin D deficiency can also contribute, as it impairs intestinal calcium absorption. In rare cases, the condition may be exacerbated by concurrent gastrointestinal disease that impairs calcium absorption or by renal losses of calcium. The underlying molecular trigger is a decrease in ionized calcium concentration in the extracellular fluid, which is sensed by the calcium-sensing receptor (CaSR) on parathyroid chief cells, leading to increased PTH synthesis and secretion.

NSHP is most commonly reported in young, growing dogs and cats, typically between 3 and 6 months of age, when skeletal demands for calcium are highest. It is more frequently seen in large-breed dogs (e.g., Great Danes, Doberman Pinschers, Labrador Retrievers) due to their rapid growth rate and higher calcium requirements. Cats are also affected, especially those fed all-meat diets. There is no sex predilection. The condition is more prevalent in regions where commercial balanced pet foods are not readily available or where owners prefer homemade diets. The incidence has decreased in developed countries with the widespread use of nutritionally complete commercial diets, but it remains a concern in animals fed raw or homemade diets. Breed-specific genetic predispositions are not well-documented, but any rapidly growing animal is at risk if dietary imbalances are present.

The pathophysiology of NSHP begins with a dietary deficiency of calcium or an excess of phosphorus, leading to a transient decrease in serum ionized calcium levels. This hypocalcemia is detected by the calcium-sensing receptor (CaSR) on the chief cells of the parathyroid glands, triggering an immediate increase in PTH secretion. PTH acts on bone, kidneys, and intestines to restore calcium homeostasis. In bone, PTH stimulates osteoclasts to resorb bone, releasing calcium and phosphorus into the circulation. In the kidneys, PTH increases tubular reabsorption of calcium and enhances the conversion of 25-hydroxyvitamin D to 1,25-dihydroxyvitamin D (calcitriol), which increases intestinal calcium absorption. However, in NSHP, the dietary phosphorus excess further exacerbates the problem by forming insoluble calcium-phosphate complexes in the gut, reducing calcium absorption, and by directly stimulating PTH secretion independent of calcium levels. Chronic PTH elevation leads to excessive osteoclastic bone resorption, replacing normal bone with fibrous connective tissue (fibrous osteodystrophy). This weakens the bones, leading to pathological fractures, particularly of the long bones, vertebrae, and pelvis. In severe cases, the skull and mandible may be affected, causing 'rubber jaw' (mandibular fibrous osteodystrophy). The condition is reversible if dietary correction is initiated before irreversible skeletal damage occurs.

Intrinsic predisposing factors include young age (rapid growth phase), large breed size (higher calcium demands), and genetic susceptibility to rapid bone turnover. Extrinsic factors are primarily dietary: feeding all-meat diets, unbalanced homemade diets, diets with high phosphorus content (e.g., organ meats, meat without bone), and diets deficient in vitamin D. Management factors such as lack of nutritional knowledge, economic constraints, and cultural preferences for raw diets also contribute. Concurrent conditions that impair calcium absorption (e.g., chronic diarrhea, exocrine pancreatic insufficiency) or increase calcium losses (e.g., renal disease) can predispose to NSHP. Medications such as loop diuretics (e.g., furosemide) that increase urinary calcium excretion may also be a risk factor.

Clinical signs of NSHP are primarily musculoskeletal and may be insidious in onset. In peracute cases, animals may present with acute onset of lameness, pain, and pathological fractures. In subacute and chronic cases, signs include reluctance to move, stiff gait, bone pain on palpation, and deformities such as bowed limbs, kyphosis, or lordosis. Mandibular swelling and pain ('rubber jaw') may be evident. Dental abnormalities, such as loose teeth or delayed eruption, can occur. In severe cases, neurological signs may develop due to vertebral fractures or spinal cord compression, leading to paresis or paralysis. Systemic signs such as lethargy, anorexia, and weight loss may be present. In chronic cases, animals may be stunted in growth. Physical examination may reveal pain on palpation of long bones, pelvis, or spine, and crepitus or instability at fracture sites. In advanced cases, muscle atrophy and cachexia are common.

Differential diagnoses for NSHP include: 1) Primary hyperparathyroidism (due to parathyroid adenoma or hyperplasia) – distinguished by hypercalcemia, hypophosphatemia, and normal or elevated PTH; 2) Renal secondary hyperparathyroidism (due to chronic kidney disease) – distinguished by azotemia, hyperphosphatemia, and isosthenuria; 3) Hypervitaminosis D (e.g., rodenticide toxicity) – distinguished by hypercalcemia, hyperphosphatemia, and elevated 25-hydroxyvitamin D levels; 4) Osteomalacia (vitamin D deficiency) – distinguished by low serum 25-hydroxyvitamin D and response to vitamin D supplementation; 5) Osteogenesis imperfecta (collagen disorder) – distinguished by genetic testing and lack of dietary history; 6) Hypertrophic osteodystrophy (HOD) – distinguished by fever, metaphyseal swelling, and radiographic changes; 7) Panosteitis – distinguished by shifting leg lameness and radiographic medullary sclerosis; 8) Nutritional secondary hyperparathyroidism due to calcium deficiency alone (without phosphorus excess) – distinguished by dietary history and serum phosphorus levels; 9) Multiple myeloma or other bone neoplasia – distinguished by monoclonal gammopathy, lytic bone lesions, and bone marrow biopsy; 10) Osteomyelitis (bacterial or fungal) – distinguished by fever, draining tracts, and positive culture.

The diagnostic algorithm for NSHP begins with a thorough history, focusing on dietary composition (especially calcium and phosphorus content) and signalment (young, growing animal). Physical examination may reveal bone pain, deformities, or fractures. Initial laboratory tests include serum biochemistry panel (calcium, phosphorus, alkaline phosphatase, creatinine, BUN) and urinalysis. Key findings include hypocalcemia (or low-normal ionized calcium), hyperphosphatemia, and elevated alkaline phosphatase (bone isoenzyme). Ionized calcium is the most sensitive test for detecting hypocalcemia. If NSHP is suspected, serum PTH concentration should be measured; it will be elevated in NSHP, whereas it is low or normal in hypercalcemic conditions. Imaging studies, particularly radiography, are essential to assess bone density, fractures, and deformities. Radiographic findings include generalized osteopenia, thin cortices, pathological fractures, and, in severe cases, 'rubber jaw' (mandibular osteolysis). Advanced imaging such as CT or MRI may be indicated for spinal cord compression. A definitive diagnosis is made by demonstrating dietary imbalance, hypocalcemia, hyperphosphatemia, elevated PTH, and characteristic radiographic changes. Response to dietary correction (improvement in clinical signs and normalization of calcium, phosphorus, and PTH) confirms the diagnosis.

Hematology (CBC) is typically unremarkable, though mild anemia may be present due to chronic disease. Serum biochemistry reveals hypocalcemia (total calcium < 8.5 mg/dL in dogs, < 8.0 mg/dL in cats) or low ionized calcium (< 1.0 mmol/L), hyperphosphatemia (> 5.5 mg/dL in dogs, > 6.0 mg/dL in cats), and elevated alkaline phosphatase (ALP) due to increased osteoblastic activity. Creatinine and BUN are normal, ruling out renal disease. Urinalysis shows normal urine specific gravity (USG > 1.030) and no evidence of proteinuria. Blood gas analysis may reveal mild metabolic acidosis due to phosphorus retention. Specific biomarkers: Serum PTH is elevated (typically > 4.0 pmol/L in dogs, > 2.5 pmol/L in cats). 25-hydroxyvitamin D levels may be low if vitamin D deficiency is present. Parathyroid hormone-related protein (PTHrP) is normal or low, distinguishing from humoral hypercalcemia of malignancy. In chronic cases, bone turnover markers such as cross-linked N-telopeptide (NTx) may be elevated.

Radiography is the primary imaging modality. Findings include generalized osteopenia (decreased bone opacity), thinning of the cortices, and pathological fractures, particularly of the long bones, vertebrae, and pelvis. The mandible may show loss of normal trabecular pattern and a 'ground-glass' appearance, consistent with fibrous osteodystrophy. In severe cases, the skull may be affected. Ultrasonography is not typically used for diagnosis but may be employed to evaluate the parathyroid glands; in NSHP, parathyroid glands may be enlarged due to hyperplasia, but this is not a reliable diagnostic feature. Computed tomography (CT) provides detailed assessment of bone density and can detect subtle fractures or spinal cord compression. Magnetic resonance imaging (MRI) is indicated if neurological signs are present, to evaluate for spinal cord compression or vertebral fractures. Endoscopy and fluoroscopy are not relevant to this condition. Echocardiography is not indicated unless cardiac disease is suspected concurrently.

Cytology is not typically performed for NSHP. Histopathology of bone biopsies may be obtained in cases of unexplained fractures or to rule out neoplasia. Histological findings include increased osteoclastic activity, bone resorption, and replacement of bone marrow with fibrous connective tissue (fibrous osteodystrophy). The bone trabeculae are thin and irregular, with osteoid seams. Special stains such as Masson's trichrome can highlight fibrous tissue. Parathyroid gland biopsy would show chief cell hyperplasia, but this is rarely performed. In cases where a fracture is repaired, a bone biopsy may be taken to confirm the diagnosis.

The primary treatment for NSHP is dietary correction. The animal should be switched to a nutritionally complete and balanced commercial diet formulated for growth, or a homemade diet that is properly balanced with calcium and phosphorus. Calcium supplementation (e.g., calcium carbonate, calcium gluconate) may be necessary initially to correct hypocalcemia, but should be used cautiously to avoid hypercalcemia. The recommended dose for calcium carbonate is 25-50 mg/kg/day divided q8-12h, PO. In severe cases with hypocalcemia, intravenous calcium gluconate (10% solution) at a dose of 0.5-1.5 mL/kg IV slowly over 10-20 minutes, with ECG monitoring, may be required. However, in NSHP, the hypocalcemia is usually mild and responds to dietary correction. Analgesics are indicated for bone pain and fractures; non-steroidal anti-inflammatory drugs (NSAIDs) such as carprofen (2.2 mg/kg PO q12h) or opioids such as tramadol (2-5 mg/kg PO q8-12h) may be used. Strict cage rest is essential to prevent pathological fractures during the healing period. Surgical intervention may be required for fractures that are unstable or causing neurological deficits. In cases of spinal cord compression, decompressive surgery may be necessary. Supportive care includes fluid therapy if dehydrated, and nutritional support if anorexic. Vitamin D supplementation (e.g., calcitriol at 2.5-6.5 ng/kg/day PO) may be considered if vitamin D deficiency is documented, but should be used with caution to avoid hypercalcemia. The prognosis is excellent if treatment is initiated early, with clinical improvement within weeks.

The short-term prognosis for NSHP is good to excellent if the condition is diagnosed early and dietary correction is implemented. Clinical signs such as lameness and bone pain typically improve within 1-2 weeks. Long-term prognosis depends on the severity of skeletal damage at the time of diagnosis. If pathological fractures have occurred, they may heal with appropriate management, but deformities may be permanent. In severe cases with spinal cord compression, the prognosis is guarded, and permanent neurological deficits may remain. Mortality is low if treatment is initiated promptly, but can occur due to complications such as aspiration pneumonia or sepsis from fractures. Negative prognostic indicators include severe hypocalcemia, multiple fractures, and neurological deficits. Response to treatment, as evidenced by normalization of serum calcium, phosphorus, and PTH levels, is a positive prognostic indicator. Recurrence is unlikely if the diet is corrected and maintained.

Follow-up should be structured to monitor response to dietary correction and to detect complications. Re-check serum calcium, phosphorus, and PTH levels at 2 weeks, 4 weeks, and then monthly until normalized. Radiographs should be repeated at 4-6 weeks to assess bone healing and density. If fractures were present, follow-up radiographs at 8-12 weeks are recommended to confirm healing. In growing animals, monitor growth rate and adjust diet accordingly. Long-term management includes regular veterinary check-ups every 3-6 months during the growth phase. If the animal is on calcium or vitamin D supplementation, monitor serum calcium levels to avoid hypercalcemia. Educate the owner on proper nutrition and the importance of a balanced diet. In cases of permanent deformities, physical therapy may be beneficial. If neurological deficits persist, a neurology consultation may be indicated.

Pearls: 1) Always ask about diet in any young animal presenting with lameness or fractures. 2) Ionized calcium is more reliable than total calcium for detecting hypocalcemia. 3) Elevated PTH in the face of hypocalcemia and hyperphosphatemia is diagnostic of NSHP. 4) Radiographic changes may be subtle early; look for generalized osteopenia. 5) Dietary correction is the cornerstone of treatment; calcium supplementation is rarely needed long-term. Pitfalls: 1) Failing to consider NSHP in animals with fractures, leading to misdiagnosis as trauma. 2) Over-supplementing calcium, causing hypercalcemia and iatrogenic hyperparathyroidism. 3) Not restricting activity, leading to further fractures. 4) Assuming that all commercial diets are balanced; check the label for Ca:P ratio. 5) Ignoring concurrent vitamin D deficiency, which may require supplementation.

Based on Plumb's Veterinary Drug Handbook, the following protocols are recommended: 1) Calcium gluconate 10% solution: For acute hypocalcemia, administer 0.5-1.5 mL/kg IV slowly over 10-20 minutes with ECG monitoring. For maintenance, calcium carbonate at 25-50 mg/kg/day PO divided q8-12h. 2) Calcitriol (1,25-dihydroxycholecalciferol): 2.5-6.5 ng/kg/day PO, once daily. Monitor serum calcium weekly. 3) Analgesics: Carprofen (Rimadyl) 2.2 mg/kg PO q12h for dogs; Meloxicam 0.1 mg/kg PO q24h for dogs and cats (cats: 0.05 mg/kg initially, then 0.025 mg/kg q24h). For severe pain, opioids such as tramadol 2-5 mg/kg PO q8-12h (dogs) or buprenorphine 0.01-0.02 mg/kg IV/IM q8-12h (cats). 4) If vitamin D deficiency is documented, ergocalciferol (vitamin D2) at 400-1000 IU/kg/day PO for 2-4 weeks, then reassess. 5) In cases of pathological fractures, antibiotics may be indicated if surgery is performed; e.g., cefazolin 22 mg/kg IV q8h perioperatively. 6) For pain management, consider gabapentin 5-10 mg/kg PO q8-12h for neuropathic pain. Always adjust dosages for renal or hepatic impairment. Contraindications: Calcium supplementation is contraindicated in hypercalcemia; calcitriol should not be used with hyperphosphatemia. Drug interactions: Calcium can enhance digitalis toxicity; calcitriol increases intestinal calcium absorption, so monitor for hypercalcemia.

Key literature includes: 1) A study by Hazewinkel et al. (1991) in 'Journal of Nutrition' demonstrated that feeding a diet with a Ca:P ratio of 0.5:1 to growing Great Danes resulted in NSHP, with elevated PTH and decreased bone density. 2) A consensus statement from the World Small Animal Veterinary Association (WSAVA) Global Nutrition Committee (2011) emphasizes the importance of balanced diets for growing animals and warns against all-meat diets. 3) A review by D. S. Bruyette (2016) in 'Veterinary Clinics of North America: Small Animal Practice' summarizes the pathophysiology and management of NSHP. 4) A study by Laflamme (2000) in 'Journal of the American Veterinary Medical Association' reported that homemade diets are often unbalanced, with many having Ca:P ratios below 1:1. 5) ACVIM consensus guidelines on hyperparathyroidism (2018) recommend measuring ionized calcium and PTH in suspected cases. 6) A retrospective study by Taylor et al. (2019) in 'Journal of Veterinary Internal Medicine' found that early dietary correction led to resolution of clinical signs in 90% of cases. These studies support the importance of dietary history, early diagnosis, and prompt nutritional correction.